Press Releases
Apr 6, 2017- Preclinical results demonstrate potential of Company's Cellspan Esophageal Implant to facilitate esophageal regeneration after resection -Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and...
Mar 28, 2017Biostage to present in the 3D Printing and BioEngineering panel on Thursday, March 30 at 2:30 PM ETBiostage, Inc. (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the...
- Mar 16, 2017- Dr. La Francesca responsible for leading scientific and clinical advancement of Company's lead program, Cellspan esophageal implants, into human clinical trials before the end of 2017
Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the...
Mar 9, 2017- 2016 marked by establishing a strong foundation on operational, clinical and regulatory fronts in anticipation of a transformational year aheadBiostage, Inc. (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the...
- Mar 2, 2017Conference Call with Live Audio Webcast on Thursday, March 9th at 9:00 AM ET
Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the...
